Business
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
FORT MYERS, Fla., February 12, 2026--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.
About this update from Neogenomics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2390,"height":984,"url":"https://media.zenfs.com/en/business-wire.com/4c1170c308eff4a17a5b41666f522764"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jNhOR8YziXJ9GchRtjjrDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM5NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4c1170c308eff4a17a5b41666f522764","width":960,"height":395},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/OaC6qyTPHTx9nUdpiuwXVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05ODg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4c1170c308eff4a17a5b41666f522764","width":1200,"height":494}},"lazy":false},{"type":"text","content":"New integrated testing approach provides potential to deliver earlier biomarker insights, reduce diagnostic uncertainty in complex cancer cases, and enable confident clinical decisions","length":184,"tagName":"p","attribs":{}},{"type":"text","content":"FORT MYERS, Fla., February 12, 2026--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the availability of PanTracer Pro, a new addition to the PanTracer® Family, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patients with advanced-stage solid tumors.","length":422,"tagName":"p"},{"type":"text","content":"As precision oncology continues to evolve, clinicians face growing diagnostic complexity, increasing biomarker requirements, and mounting pressure to initiate treatment quickly, often before a complete molecular profile is available. Fragmented testing workflows, sequential ordering, and tissue limitations can delay care and introduce uncertainty at critical decision points. PanTracer Pro was developed to address these challenges more comprehensively and earlier in the diagnostic pathway.","length":493,"tagName":"p"},{"type":"text","content":""Every delay or unanswered question in the diagnostic process can affect how quickly patients begin treatment," said Tony Zook, chief executive officer at NeoGenomics. "PanTracer Pro is designed to help clinicians get the information they need earlier and more reliably, so care teams can plan next steps with greater clarity and c...